TY - JOUR
T1 - Clinical observation of docetaxel in the treatment of non-small cell lung cancer and breast cancer
AU - Hao, Xuezhi
AU - Zhang, Xiangru
AU - Sun, Yan
PY - 2005
Y1 - 2005
N2 - Objective: To evaluate the efficacy and safety of docetaxel (Wanle) and docetaxel (Wanle) plus cisplatin regimen in patients with breast cancer and non-small cell lung cancer. Methods: 1) Single agent regimen: patients of breast cancer (group A) and NSCLC (group B)were treated with docetaxel 75mg/m 2 in the first day, and the schedule was repeated every 21 days. 2) Combination regimen: patients with breast cancer were randomly assigned to receive docetaxel (Wanle) 70mg/m 2 iv + cisplatin 80mg/m 2 (group C) treatment or taxotere 70mg/m 2 iv + cisplatin 80mg/m 2 iv treatment (group D), the schedule was repeated every 21 days. Patients with NSCLC were also randomly assigned to regimens of docetaxel (Wanle)+cisplatin (group E) and Taxotere + cisplatin (group F). Results: A total of 138 of the 147 patients were evaluative for efficacy and 141 of the patients were evaluative for side effects. Overall response rate of group A, B, C, D, E , F was 21.7%, 6.1%, 60.0%, 35%, 23.8% and 28.6%, respectively. The major side effects were myelosuppression, neutropenia, nausea, vomiting and alopecia. Conclusion: The docetaxel (Wanle) is effective and well tolerated in the treatment of advanced NSCLC and breast cancer. Efficacy and side effect of docetaxel (Wanle) are similar to the imported Taxotere.
AB - Objective: To evaluate the efficacy and safety of docetaxel (Wanle) and docetaxel (Wanle) plus cisplatin regimen in patients with breast cancer and non-small cell lung cancer. Methods: 1) Single agent regimen: patients of breast cancer (group A) and NSCLC (group B)were treated with docetaxel 75mg/m 2 in the first day, and the schedule was repeated every 21 days. 2) Combination regimen: patients with breast cancer were randomly assigned to receive docetaxel (Wanle) 70mg/m 2 iv + cisplatin 80mg/m 2 (group C) treatment or taxotere 70mg/m 2 iv + cisplatin 80mg/m 2 iv treatment (group D), the schedule was repeated every 21 days. Patients with NSCLC were also randomly assigned to regimens of docetaxel (Wanle)+cisplatin (group E) and Taxotere + cisplatin (group F). Results: A total of 138 of the 147 patients were evaluative for efficacy and 141 of the patients were evaluative for side effects. Overall response rate of group A, B, C, D, E , F was 21.7%, 6.1%, 60.0%, 35%, 23.8% and 28.6%, respectively. The major side effects were myelosuppression, neutropenia, nausea, vomiting and alopecia. Conclusion: The docetaxel (Wanle) is effective and well tolerated in the treatment of advanced NSCLC and breast cancer. Efficacy and side effect of docetaxel (Wanle) are similar to the imported Taxotere.
KW - Breast cancer
KW - Docetaxel
KW - Non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=35948991508&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:35948991508
VL - 32
SP - 1064
EP - 1066
JO - Chinese Journal of Clinical Oncology
JF - Chinese Journal of Clinical Oncology
SN - 1672-7118
IS - 18
ER -